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Ptaged Initial Percutaneous Coronary Intervention
ollowed by Valve Surgery (“Hybrid Approach”) for
atients With Complex Coronary and Valve Disease
ohn G. Byrne, MD, FACC,* Marzia Leacche, MD,* Daniel Unic, MD,* James D. Rawn, MD,*
aniel I. Simon, MD, FACC,† Campbell D. Rogers, MD, FACC,† Lawrence H. Cohn, MD, FACC*
oston, Massachusetts
OBJECTIVES The goal of this study was to determine if a “hybrid” approach to the treatment of complex
combined coronary and valve disease is superior to the results predicted by a Society of
Thoracic Surgeons’ (STS) algorithm with conventional coronary artery bypass graft (CABG)/
valve surgery in high-risk patients.
BACKGROUND With advancements in percutaneous coronary interventions (PCIs), some patients requiring
coronary revascularization and valve surgery may benefit from a hybrid approach involving
initial planned PCI followed by valve surgery, rather than conventional CABG/valve surgery.
METHODS We retrospectively analyzed 26 consecutive patients with coronary artery and valve disease
who underwent planned initial PCI followed by valve surgery during the same hospital stay
between September 1997 and August 2003. We calculated the predicted mortality at the time
of PCI and compared it with the observed mortality.
RESULTS There were 12 male and 14 female patients with a median age of 72 years (range 53 to 91
years). Balloon angioplasty was performed in all patients, followed by stenting in 22 (85%)
patients. Within a median of 5 days (range 0 to 14 days), 15 patients (58%) underwent
primary and 11 patients (42%) underwent re-operative valve surgery. Operative mortality was
1 of 26 patients (3.8%), dramatically lower than the STS-predicted mortality of 22%. Median
blood loss was 900 ml, and 22 patients (85%) required blood transfusions. Survival at 1, 3, and
5 years was 78%, 56%, and 44%, respectively.
CONCLUSIONS Hybrid initial PCI followed by staged valve surgery represents an excellent alternative to
conventional CABG/valve surgery in some high-risk patients, particularly those who present
in shock after myocardial infarction. Lower mortality rates come at the cost of more bleeding
and transfusion requirements. (J Am Coll Cardiol 2005;45:14–8) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.050College of Cardiology Foundation
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ined with valve surgery as well as some re-operative
alve/CABG operations are high-risk procedures with a
odern operative mortality for each approaching 20%
1–4). The optimal treatment for these patients is not firmly
stablished (5).
With our recently developed techniques for minimally
nvasive primary (6) and re-operative (7) valve surgery, the
hybrid” approach makes particular sense. We have previ-
usly shown that the minimally invasive approach for
e-operative valve surgery minimizes the possibility of graft
njury and avoids unnecessary mediastinal dissection,
hereby decreasing bleeding complications (7–9). In the
resence of verified coronary or graft disease, an initial
taged percutaneous coronary intervention (PCI) might
elp avoid excessive surgery, enabling patients to benefit
ully from minimally invasive valve surgery.
From the Divisions of *Cardiac Surgery and the †Cardiovascular Division,
righam and Women’s Hospital, Boston, Massachusetts. Supported by the BWH
eart Research Fund of Brigham & Women’s Hospital. Presented at the Annual
cientific Session of the American College of Cardiology, March 7 to 10, 2004, New
rleans, Louisiana.s
Manuscript received July 22, 2004; revised manuscript received September 18,
004, accepted September 21, 2004.We hypothesized that the hybrid approach—consisting
f planned initial PCI of the culprit native coronary artery or
ABG followed by valvular surgery after patient stabiliza-
ion—would have better outcomes than those predicted by
he Society of Thoracic Surgeons (STS) algorithm for
ombined CABG/valve surgery after acute coronary syn-
romes (ACS) and patients undergoing complex valve
eoperations.
ETHODS
fter obtaining the institutional review board approval,
e retrospectively reviewed the medical records of 26
onsecutive patients who underwent PCI followed by
alve surgery from September 1997 to August 2003. The
ecision for the hybrid approach was made jointly by the
eferring and interventional cardiologist and the cardiac
urgeon. In all patients, coronary and valvular lesions
ere documented by diagnostic catheterization and echo-
ardiography, respectively, and hemodynamic status was
stablished in the catheterization laboratory. After a
reatment plan was established, the interventional cardi-
logist proceeded with PCI (balloon angioplasty with or
ithout stenting) of the culprit lesion (native vessels oraphenous vein grafts). After a period of hemodynamic
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January 4, 2005:14–8 Hybrid Approach for Coronary and Valve Diseasetabilization during which patients received antiaggrega-
ion treatment, valve surgery was performed, typically
ithin a week of PCI. Patients requiring re-operative
alvular procedures in which concomitant CABG was not
eeded were approached through a minimally invasive
ncision when appropriate (7,8).
efinitions of pre-PCI patient characteristics. Acute
yocardial infarction (AMI): creatine-kinase values 2
imes the upper limit of the normal, or troponin T or I
aximal level 1.0 ng/ml on one occasion within 24 h of
linical event and changes from the baseline or of the
T-T in serial electrocardiograms; unstable angina: an-
ina at rest or new onset of exertional angina of at least
anadian Cardiovascular Society class III; low cardiac
utput syndrome: cardiac index 2.0 l/min/m2 requiring
notropic support to maintain a systolic pressure 90 mm
g for at least 30 min, and/or placement of an intra-
ortic balloon pump; cardiogenic shock: systolic blood
ressure 80 mm Hg or cardiac index 1.8 despite
aximal treatment; renal insufficiency: baseline creatinine
evel 1.5 mg/dl.
efinitions of perioperative events. Hospital mortality:
eath for any reason occurring within 30 days after the
urgery or after 30 days occurring during the same hospi-
alization; low cardiac output syndrome: cardiac index 2.0
/min/m2, requiring inotropic support to maintain a systolic
ressure 90 mm Hg for at least 30 min, and/or placement
f an intra-aortic balloon pump and/or ventricular assist
evice; bleeding: necessity of re-exploration of the thorax for
uspected bleeding during the postoperative period; stroke:
vidence in the postoperative period of a new central
eurological deficit persisting for 72 h, whereas, if the
eurological deficit resolved in 72 h, it is considered a
ransient ischemic attack.
TS risk algorithm for predicted surgical mortality at the
ime of PCI. Predicted mortality was calculated utilizing
lgorithms for the pre-operative calculation of risk for AVR
CABG and MVR CABG provided by the STS. These
lgorithms are based on data collected between 1994 and
997 from approximately 100,000 of these combined
ABG/valve procedures. Algorithms for outcomes since
997 are not yet available. However, unadjusted and risk-
djusted mortalities for these operations have not signifi-
antly changed.
tatistical analysis. Data are expressed as the median value
r percentage. Long-term survival rates were calculated
Abbreviations and Acronyms
ACS  acute coronary syndrome
AMI  acute myocardial infarction
CABG  coronary artery bypass graft/grafting
PCI  percutaneous coronary intervention
STS  Society of Thoracic Surgeonssing the Kaplan-Meier method. Statistical software pack- dge STATA 7.0 for Windows (STATA, College Station,
exas) was used to calculate our results.
ESULTS
rom September 1997 to August 2003, 26 patients under-
ent staged initial PCI followed by valve surgery; pre-PCI
ata documenting the high-risk profile of this patient
ohort are summarized in Table 1. Indications for PCI are
ummarized in Table 2. The median number of vessels
ndergoing PCI was 2 (range 1 to 3), with balloon angio-
lasty performed in 26 patients (100%) and stenting in 22 of
6 patients (85%). Drug-eluting stents were used in 3 of 26
atients (12%). Distribution of vessels undergoing PCI was
eft anterior descending coronary in 30%, saphenous vein
rafts in 11%, LIMA-left anterior descending coronary
rtery graft in 4%, obtuse marginal coronary in 19%, left
ircumflex coronary in 23%, and right coronary artery in
9%. Surgical procedures are summarized in Table 3.
oncomitant CABG to non-culprit vessels was performed
n 10 of 26 patients (38%): 9 primary mitral and 1 primary
ortic. No re-operative patients underwent concomitant
ABG. Median cardiopulmonary bypass time was 141 min
range 60 to 249 min) with a median aortic clamp time of 91
in (range 10 to 142 min). Twenty-six patients (100%)
ere receiving aspirin at the time of surgery, and 18 of 26
atients (69%) were receiving clopidogrel. Postoperative
leeding and other complications were common (Table 4).
One patient (3.8%) died during the postoperative course.
his 75-year-old patient developed acute papillary muscle
upture and cardiogenic shock after AMI. The coronary
esion was successfully managed by PCI and stenting.
mmediate mitral valve replacement was required because of
evere mitral regurgitation. Massive gastrointestinal bleed-
ng on postoperative day 28 was the immediate cause of
able 1. Pre-PCI Patient Characteristics
(n  26)
edian age (yrs) 72 (range 53–91)
emale 14 (54%)
edian EF (%) 37 (range 17–60)
ean NYHA functional class 3.5  0.6
ean CCS class 3.5  0.6
ntubation 7 (27%)
ABP 9 (35%)
reatinine 1.5 mg/dl 10 (38%)
OPD 7 (27%)
iabetes 8 (30%)
rgent 20 (77%)
mergency 6 (13%)
rior heart surgery 11 (42%)
edian PAP (mm Hg) 31 (range 16–53)
cute MI 11 (42%)
CS  Canadian Cardiovascular Society; COPD  chronic obstructive pulmonary
isease; EF ejection fraction; IABP intra-aortic balloon pump; MImyocardial
nfarction; NYHA  New York Heart Association; PAP  pulmonary artery
ressure; PCI  percutaneous coronary intervention.eath.
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Hybrid Approach for Coronary and Valve Disease January 4, 2005:14–8The median predicted mortality for conventional valve/
ABG surgery at the time of PCI for this cohort of patients
as 22% (range 3.5% to 63.5%) according to the STS risk
tratification algorithms (Fig. 1). Survival at 1, 3, and 5 years
as 78%, 56%, and 44%, respectively (Fig. 2). There were
o cases of subacute stent thrombosis or postoperative
-wave myocardial infarction.
ISCUSSION
he principal finding in this report is that “hybrid” initial
CI followed by staged valve surgery represents an excellent
lternative to conventional high-risk CABG/valve surgery
n patients who present after an ACS, and in some patients
ho require complex re-operative valve surgery. A lower
perative mortality rate (3.8% vs. 22%) compared with that
redicted by the STS algorithm was achieved at the cost of
ncreased rates of reoperation for bleeding, greater blood
oss, and higher transfusion requirements.
Aspirin and platelet inhibitors are universal adjuvant
herapies to PCI. All of our patients received aspirin, and
9% received additional clopidogrel in the period between
CI and surgery. The median blood loss after surgery for
he entire cohort was almost 1 l. A total of 85% received
ome type of blood transfusion, and our re-operation rate
or bleeding was 8%. The only death in the series was
Table 2. Indications for PCI
Unstable angina
Median time between symptoms and PCI (h)
Low cardiac output syndrome (IABP or inotropes
AMI
Time between AMI and PCI
6 h
24 h to 7 days
Q-wave AMI
Non–Q-wave AMI
Troponin I (ng/ml)
Cardiogenic shock (systolic blood pressure 80 mm
Low cardiac output syndrome (IABP or inotropes)
Acute mitral regurgitation
PCI before complex reoperative valve surgery
AMI  acute myocardial infarction; IABP  intra-aortic b
able 3. Valve  CABG Surgery
(n  26)
edian time from PCI to surgery (days) 5 (range 0–14)
eoperative valve surgery 11 (42%)
Mitral (n  8) (6 right thoracotomy)
Aortic (n  3) (1 min-inv)
rimary valve surgery 15 (58%)
Mitral (n  13)
Aortic (n  1) (min-inv)
Double (n  1)ABG  coronary artery bypass graft; min-inv  minimally invasive; PCI 
ercutaneous coronary intervention. Ielated, in part, to a bleeding complication. Although our
tudy documented a high incidence of bleeding complica-
ions, this was not accompanied by high mortality. Despite
otent antiplatelet agents, a sensible algorithm for dosing
nd timing may help minimize bleeding risk. Subacute stent
hrombosis, as reported after noncardiac surgery where
ntiplatelet agents are stopped (10), was not observed in this
tudy, likely the result of the antiplatelet effects of cardio-
ulmonary bypass as well as the routine use of postoperative
lopidogrel.
In patients with increased risk for bleeding, the choice of
urgical approach gains greater importance. We have pre-
iously documented benefits in terms of decreased blood
oss and transfusion requirements in patients undergoing
oth primary and re-operative minimally invasive valvular
urgery (6–9). The minimally invasive approach is particu-
arly useful in re-operative surgery and in some stabilized
atients after an ACS. Thus, a tailored approach to meet
pecific patient needs is required.
Because most patients in this study (92%) presented with
n ACS, the hybrid approach would seem of obvious benefit
o most clinicians, with the goal of first stabilizing the
(n  26)
13 (50%)
24 (range 3–240)
4
11 (42%)
36 (range 1–100)
3
8
5
6
20 (range 1–160)
espite IABP) 4 (15%)
6 (23%)
1 (4%)
2 (8%)
pump; PCI  percutaneous coronary intervention.
able 4. Bleeding and Other Complications
(n  26)
eoperation for bleeding 2 (8%)
ny blood transfusion 22 (85%)
edian blood loss (ml) 900 (range 200–3,000)
edian packed red cell units 3 (range 0–9)
edian fresh frozen plasma units 1 (range 0–10)
edian platelet units 1 (range 0–6)
edian cell saver units 3 (range 0–5)
troke 1 (4%)
ermanent pacemaker 3 (12%)
racheostomy 1 (4%)
ialysis 4 (16%)
ow cardiac output syndrome 12 (48%)
ew IABP 3 (12%)
edian length of stay (days) 17 (range 6–24)
edian ICU length of stay (days) 4 (range 2–11))
Hg dABP  intra-aortic balloon pump; ICU  intensive care unit.
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January 4, 2005:14–8 Hybrid Approach for Coronary and Valve Diseaseoronary lesions and then, during the same hospital admis-
ion, addressing the valve lesion. Although performing
e-operative valve surgery in the presence of aspirin and
lopidogrel might seem anathema to most surgeons, in two
atients we judged that the risk posed by dissecting the
eart for concomitant CABG—in the absence of clopi-
ogrel—was greater than the risk posed by bleeding in the
etting of powerful antiplatelet medications. Ideally, these
atients would be best managed by either a longer staging
uration so that the clopidogrel can be stopped (three to six
onths with drug-eluting stents), or by a very short staging
uration (under 6 h), so that clopidogrel’s actions are just
eginning to take effect once the surgery has been com-
leted. One way to accomplish the shorter staging approach
s to initially perform the PCI in the catherization labora-
ory and then directly transfer the patient to the operating
igure 1. Observed versus predicted operative mortality. Society of Tho-
acic Surgeons algorithm for pre-operative risk assessment for valve/
oronary artery bypass grafting at time of percutaneous coronary interven-
ion.Figure 2. Kaplan-Meier curve for ovoom for re-operative valve surgery. However, this approach
ould require not only holding an operating room open, but
lso two hospital fees for the use of both the catheterization
aboratory and the operating room, as well as additional
and-offs among care providers, making it an inefficient and
ost-ineffective approach. Another solution may be to de-
elop hybrid operating rooms/catheterization suites where
CI could be done first followed immediately by re-
perative valve surgery. Such hybrid suites could also be
sed for elective minimally invasive primary valve surgery
ith accompanying PCI. Recently, we have been perform-
ng elective cases involving both procedures in a staged
ashion more often, but, without hybrid suites, timing and
oordination are critical.
None of the patients with previous CABG in this study
ndergoing re-operative valve surgery received additional
rafts, but rather they had previous vein grafts or native
oronaries stented as needed. We believe that a signifi-
ant left anterior descending coronary artery lesion
hould be treated with a LIMA graft when possible, and
on-left anterior descending coronary artery native ves-
els or vein grafts treated with PCI. Recent improve-
ents in PCI techniques and stent design may offer safer
ntervention for diseased grafts and prolong reestablished
atency (11,12).
Our operative mortality rate is far below that predicted by
he STS algorithm. We used pre-PCI data in the STS
lgorithm to calculate the predicted mortality for emergency
alve  CABG at the time of PCI in order to document the
enefits of PCI to stabilize patients before valve surgery.erall survival. Pts.  patients.
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Hybrid Approach for Coronary and Valve Disease January 4, 2005:14–8tatistical analysis to compare the predicted versus the
bserved mortality rates was not possible because the STS
lgorithm predicts a percent likelihood of death for each
atient, thereby generating a range of percentages (3.5% to
3.5%). Observed mortality, on the other hand, is a discrete
ariable (alive or dead). However, even if statistical signifi-
ance is not achieved, the difference in mortality (3.8% vs.
2%) using the hybrid approach certainly seems clinically
ignificant. Our five-year survival of 44% correlates with
reviously reported results (4) and underscores the poor
atients substrate represented by this cohort.
tudy limitations. This was a single-center retrospective
tudy of a heterogeneous group of patients with mixed valve
nd coronary lesions requiring both primary and re-do
ardiac procedures, in whom a variety of PCI procedures
ere performed. In addition, patients were selected for PCI
n the basis of favorable anatomy for this procedure. A
arger study will be needed to make more definitive
ecommendations.
onclusions. Our data demonstrate that, for selected pa-
ients with mixed coronary and valvular heart disease, a team
pproach whereby coronary lesions are treated in the cath-
terization laboratory and then valvular disease is treated in
he operating room provides early outcomes far superior to
hose predicted for valve/CABG surgery. The “hybrid”
pproach will likely become more common, particularly for
omplex patients who require a tailored strategy to help
inimize risk.
eprint requests and correspondence: Dr. John G. Byrne,
epartment of Cardiac Surgery, Vanderbilt University Medical
enter, Nashville, Tennessee 37232-8815. E-mail: john.byrne@anderbilt.edu.EFERENCES
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